Company
Amneal
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
12
11 still marketed
Novel approvals
1
Approvals since 2021
7
Originals and new uses
Phase 3 trials
13
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 313
Recent approvals
Originals and efficacy supplements, newest first.
- Sodium Bicarbonate approved Jul 9, 2026
- Oziltus approved Dec 19, 2025
- Boncresa approved Dec 19, 2025
- Brekiya (Autoinjector) approved May 14, 2025
- Pyridostigmine Bromide approved Oct 4, 2024
- Potassium Phosphates In 0.9% Sodium Chloride approved Jul 26, 2024
- Alymsys approved Apr 13, 2022
- Ongentys approved NovelApr 24, 2020
- Tigecycline approved Aug 2, 2018
- Zomig new use Jun 12, 2015
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Safety and Efficacy of Weekly Testosterone Cypionate Auto-Injector in Men With HypogonadismPivotal-lookingRecruiting
Amneal Pharmaceuticals, LLCIndustry
NCT07898072 · 190 participants (planned) · Start Sep 28, 2026 · Primary completion Mar 31, 2027
Drug: Testosterone Cypionate 75 mg; Testosterone cypionate 50 mg and 1 more · For: Male Hypogonadism
Sites: Santa Monica, California; DeLand, Florida; Miami Lakes, Florida · 10 sites in all
- Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.Pivotal-lookingRecruiting
Amneal Pharmaceuticals, LLCIndustry
NCT05401357 · 168 participants (planned) · Start Jun 29, 2022 · Primary completion Dec 2022
Drug: Test - Bimatoprost 0.01% Ophthalmic Solution; Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) · For: Glaucoma, Open-Angle; Ocular Hypertension
Sites: Newport Beach, California; Petaluma, California; New Smyrna Beach, Florida · 9 sites in all
Marketed drugs (11)
Newest FDA action first.
- Sodium Bicarbonate Sodium Bicarbonate · 2026
- Oziltus Denosumab-Mobz · 2025
- Boncresa Denosumab-Mobz · 2025
- Ongentys Opicapone · 2020
- Brekiya (Autoinjector) Dihydroergotamine Mesylate · 2025
- Tigecycline Tigecycline · 2018
- Potassium Phosphates In 0.9% Sodium Chloride Potassium Phosphate, Dibasic, Potassium Phosphate, Monobasic · 2024
- Activella Estradiol, Norethindrone Acetate · 1998
- Alymsys Bevacizumab-Maly · 2022
- Lioresal Baclofen · 1992
- Zomig Zolmitriptan · 2003
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.